Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wachovia Keeps Strong Buy on Andrx


The U.S.Food and Drug Administration tentatively approved Andrx's (ADRX) abbreviated new drug application for a generic version of 24-hour Claritin. Wachovia reiterated its strong buy rating on the shares.

Analyst Michael Tong tells Standard & Poor's MarketScope that the FDA action indicates the company's product approval momentum is accelerating. He says this should help ease investor concerns regarding Andrx's ability to obtain timely FDA approval. Tong notes the company was first to file on generic Claritin D-24 and is entitled to 180-day marketing exclusivity, assuming successful litigation. He says his model does not assume future contributions from any generic Claritin products in the company's pipeline, so upside potential exists. Tong has a $75 price target on the shares.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus